Literature DB >> 24412642

Neurotropin® relieves oxaliplatin-induced neuropathy via Gi protein-coupled receptors in the monoaminergic descending pain inhibitory system.

Ken Masuguchi1, Hitomi Watanabe1, Takehiro Kawashiri1, Soichiro Ushio1, Nana Ozawa1, Haruka Morita1, Ryozo Oishi1, Nobuaki Egashira2.   

Abstract

AIMS: Oxaliplatin is a key drug in the treatment of colorectal cancer, but it causes acute and chronic peripheral neuropathies. We previously reported that repeated administration of neurotropin prevents oxaliplatin-induced mechanical allodynia by inhibiting axonal degeneration in rats. In the present study, we investigated the analgesic effect of a single administration of neurotropin on oxaliplatin-induced neuropathy in rats. MAIN
METHODS: Oxaliplatin (4mg/kg) was administered intraperitoneally twice a week for 4weeks. Cold hyperalgesia was assessed using the acetone test and mechanical allodynia was evaluated using the von Frey test. KEY
FINDINGS: Repeated injection of oxaliplatin induced cold hyperalgesia on day 5 and mechanical allodynia on day 28. A single administration of neurotropin transiently relieved both pain behaviors. The analgesic effect of neurotropin was inhibited by pretreatment with 5-HT1A, 5-HT2, 5-HT3, and α2 receptor antagonists and by monoamine depletion. Moreover, the analgesic effect of neurotropin was abolished by intrathecal injection of pertussis toxin, a Gi protein inhibitor. SIGNIFICANCE: These results suggest that neurotropin is effective in relieving oxaliplatin-induced neuropathy, and that Gi protein-coupled receptors in the monoaminergic descending pain inhibitory system may be involved in the analgesic effect of neurotropin. Neurotropin may have clinical potential for the treatment of oxaliplatin-induced neuropathies.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  6-Hydroxydopamine (PubChem CID: 4624); Allodynia; G(i) protein-coupled receptors; Ketanserin (PubChem CID: 3822); Monoamine; Neurotropin; Oxaliplatin; Oxaliplatin (PubChem CID: 5310940); Prazosin (PubChem CID: 4893); WAY100635 (PubChem CID: 5684); Yohimbine (PubChem CID: 8969); p-Chlorophenylalanine (PubChem CID: 26229)

Mesh:

Substances:

Year:  2014        PMID: 24412642     DOI: 10.1016/j.lfs.2013.12.229

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  5 in total

1.  Neurotropin® alleviates hippocampal neuron damage through a HIF-1α/MAPK pathway.

Authors:  Wen-Li Fang; De-Qiang Zhao; Fei Wang; Mei Li; Sheng-Nuo Fan; Wang Liao; Yu-Qiu Zheng; Shao-Wei Liao; Song-Hua Xiao; Ping Luan; Jun Liu
Journal:  CNS Neurosci Ther       Date:  2017-03-07       Impact factor: 5.243

2.  Neurotropin suppresses inflammatory cytokine expression and cell death through suppression of NF-κB and JNK in hepatocytes.

Authors:  Bi Zhang; Yoon Seok Roh; Shuang Liang; Cheng Liu; Mitsuru Naiki; Koichi Masuda; Ekihiro Seki
Journal:  PLoS One       Date:  2014-12-03       Impact factor: 3.240

3.  Neurotropin alleviates rat osteocarcinoma pain via P2X3 receptor activation in the midbrain periaqueductal gray.

Authors:  Xingfeng Liu; Jingxin He; Zhi Xiao
Journal:  Iran J Basic Med Sci       Date:  2021-10       Impact factor: 2.699

4.  Neurotropin® Accelerates the Differentiation of Schwann Cells and Remyelination in a Rat Lysophosphatidylcholine-Induced Demyelination Model.

Authors:  Hozo Matsuoka; Hiroyuki Tanaka; Junichi Sayanagi; Toru Iwahashi; Koji Suzuki; Shunsuke Nishimoto; Kiyoshi Okada; Tsuyoshi Murase; Hideki Yoshikawa
Journal:  Int J Mol Sci       Date:  2018-02-08       Impact factor: 5.923

5.  Upregulation of glycosaminoglycan synthesis by Neurotropin in nucleus pulposus cells via stimulation of chondroitin sulfate N-acetylgalactosaminyltransferase 1: A new approach to attenuation of intervertebral disc degeneration.

Authors:  Daisuke Sakai; Tomoko Nakai; Shunsuke Hiraishi; Yoshihiko Nakamura; Kiyoshi Ando; Mitsuru Naiki; Masahiko Watanabe
Journal:  PLoS One       Date:  2018-08-27       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.